In a 15-patient, Phase 1, first-in-human trial, a one-time CRISPR-Cas9 gene-editing therapy safely reduced LDL cholesterol ...

CRISPR Therapeutics' CTX310 trial shows strong, sustained lipid reductions and favorable safety, boosting confidence in its ...

Launching the therapy, Dr. Jitendra Singh declared that India has officially begun its decisive march toward a Sickle ...

By reactivating a long-lost gene, researchers were able to lower uric acid levels and stop damaging fat accumulation in human ...

Earlier this month, CRISPR Therapeutics announced positive Phase 1 data for its investigational in vivo CRISPR/Cas9 therapy CTX310, which showed substantial and durable reductions in key lipid levels ...

ZUG, Switzerland and BOSTON, Sept. 09, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...

Presentations will showcase the company’s latest advances enabled by its CRISPR by Design TM approach to engineer safer and more effective in vivo genetic medicines for cardiometabolic disease ALAMEDA ...

Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025- -Phase 1 clinical data for CTX310® demonstrate robust, dose-dependent reductions in ...

Union Minister of State (Independent Charge) for Science & Technology; Earth Sciences; MoS PMO, Personnel, Public Grievances, Pensions, Atomic Energy and Space, Dr. Jitendra Singh today ...

Scribe Therapeutics highlights data underpinning its comprehensive strategy targeting key lipid drivers of ASCVD at AHA Scientific Sessions 2025 ...

We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where Thermo Fisher Scientific Inc. (NYSE:TMO) stands against the other CRISPR ...